NCT05822739View on ClinicalTrials.gov

Safety and Efficacy Study of Parkinson's Disease Gene Therapy Drug (BBM-P002)

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

May 30, 2025

Study Completion Date

December 30, 2028

Conditions
Parkinson's Disease
Interventions
DRUG

BBM-P002

Genetic: single- dose intracranial injection of BBM-P002 Neurosurgical delivery of BBM-P002 to the brain

Trial Locations (1)

410008

Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

Xiangya Hospital of Central South University

OTHER

NCT05822739 - Safety and Efficacy Study of Parkinson's Disease Gene Therapy Drug (BBM-P002) | Biotech Hunter | Biotech Hunter